5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism

Neuropharmacology
M V KingK C F Fone

Abstract

5-HT(6) receptors are expressed in brain regions associated with learning and memory, and blockade of their function increases central cholinergic and glutamatergic neurotransmission and enhances cognitive processes. This study examined the effects of acute systemic administration of two selective 5-HT(6) receptor antagonists Ro 04-6790 and SB-271046 (10 mg kg(-1) i.p.) on acquisition, consolidation, and retrieval in the novel object discrimination (NOD) task, a two-trial test of recognition memory in which rats exposed to two identical objects during a familiarisation trial can discriminate a novel from a familiar object during the subsequent choice trial, following inter-trial delays of up to 3 h. 5-HT(6) receptor antagonist administration 20 min prior to or immediately after the familiarisation trial, but not 20 min prior to the choice trial reversed the deficit in object discrimination produced by a 4 h inter-trial interval. The nootropic effects of the 5-HT(6) receptor antagonists in this task thus appear to involve enhanced consolidation. Pre-treatment with the non-competitive NMDA receptor antagonist MK-801 (0.05 mg kg(-1) i.p.) prevented the effect of Ro 04-6790 on delay-induced deficits in object discrimination. This s...Continue Reading

References

Sep 1, 1989·Neurobiology of Aging·J T Greenamyre, A B Young
Nov 1, 1988·Behavioural Brain Research·A Ennaceur, J Delacour
Jul 30, 1982·Science·R T BartusA S Lippa
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M RuatJ C Schwartz
Jan 12, 1999·British Journal of Pharmacology·A BoursonA J Sleight
Aug 6, 2000·British Journal of Pharmacology·C RoutledgeD N Middlemiss
Oct 30, 2001·Behavioural Brain Research·J P HatcherA J Hunter
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L A DawsonP Li
Nov 10, 2001·Psychopharmacology·D C Rogers, J J Hagan
Dec 1, 2001·Journal of Neural Transmission·J ThomeM Rösler
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sudabeh Shirazi-SouthallGeorge G Nomikos
May 7, 2002·Learning & Memory·Kevin B Baker, Jeansok J Kim

❮ Previous
Next ❯

Citations

Nov 11, 2009·Psychopharmacology·Katherine E BurnhamTrevor Sharp
Oct 12, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sinead E ShortallMadeleine V King
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neil UptonDavid J Virley
Jul 4, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Virginie Da Silva CostaFrançois Dauphin
Oct 28, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Jun 30, 2007·Nature Reviews. Drug Discovery·Menelas N PangalosOrest Hurko
Jun 16, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Cindy K J LiebenRudy Schreiber
Dec 29, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ellen S MitchellJohn F Neumaier
Jul 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lee E SchechterChad E Beyer
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·J Steven JacobsenMenelas N Pangalos
Aug 30, 2011·CNS Drugs·Werner J Geldenhuys, Cornelis J Van der Schyf
Jan 17, 2014·Experimental Brain Research·Mohammad SeyedabadiReza Rahimian
Oct 28, 2014·The British Journal of Nutrition·Thomas M WrightJörg-Peter W Voigt
Jul 11, 2009·Expert Review of Neurotherapeutics·Werner J Geldenhuys, Cornelis J Van der Schyf
Apr 7, 2012·Behavioural Brain Research·Sven AkkermanArjan Blokland
Feb 9, 2012·Neuropharmacology·David J HealSharon L Smith
Mar 23, 2011·Pharmacology, Biochemistry, and Behavior·Segev Barak, Ina Weiner
Feb 15, 2011·Pharmacology, Biochemistry, and Behavior·Alvin V TerryScott J Webster
Feb 12, 2011·Behavioural Brain Research·F Josef van der StaayArjan Blokland
Feb 17, 2010·Neuropharmacology·Paul T FrancisMitchell K Lai
Jan 3, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Sep 8, 2009·Neurobiology of Learning and Memory·A Huerta-RivasA Meneses
Sep 17, 2008·Bioorganic & Medicinal Chemistry Letters·Giancarlo TraniDavid R Witty

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.